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Objectives: Uric acid concentration is known to increase the prevalence of metabolic syndrome by affecting its
components, resulting in increased risk of cerebrovascular and cardiovascular diseases, and long-term lead exposure
is known to affect this serum uric acid level. In this study, we aimed to examine the association between the causes
of hyperuricemia and metabolic syndrome, and to determine whether an increased blood lead level affects
hyperuricemia.
Method: Anthropometric measurements, surveys, and blood tests were conducted between May and June 2012 in
759 men working in the steelmaking process at a domestic steel company. Workers were divided into 2 groups
according to the presence or absence of hyperuricemia, and an analysis was performed to examine its association
with metabolic syndrome. In addition, the workers were divided into 3 groups according to the blood lead level to
analyze the association between blood lead and hyperuricemia.
Results: The geometric mean (standard deviation) of the blood lead levels in the hyperuricemia group was
significantly higher than that of the healthy group (3.8 [1.8] vs. 3.3 [1.8] μg/dL). The adjusted odds ratio for metabolic
syndrome of the hyperuricemia group increased significantly to 1.787 (1.125–2.839) compared with the healthy group.
In addition, the adjusted odds ratios for the occurrence of hyperuricemia in the tertile 2 (2.61–4.50 μg/dL) and
tertile 3 groups (>4.50 μg/dL) according to blood lead level significantly increased to 1.763 (1.116–2.784) and
1.982 (1.254–3.132), respectively, compared with the tertile 1 group (< 2.61 μg/dL).
Conclusion: Hyperuricemia is believed to function as an independent risk factor for metabolic syndrome, while
lead seems to increase the serum uric acid level even at a considerably low blood level. Therefore, attention
should be given to patients with hyperuricemia and metabolic syndrome who are prone to lead exposure, and
a prospective study should be conducted to identify their causal relationship.
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According to the 2011 Statistics Korea data on domestic
causes of death, cerebrovascular and heart diseases
ranked second and third, respectively, among the 3 lead-
ing causes of death in Korea as yet [1]. Moreover, accord-
ing to a report, 278 of 731 occupational disease-related
deaths in 2011 were due to cerebrovascular and cardiovas-
cular diseases [2]. As such, the prevention of occupational
cerebrovascular and cardiovascular diseases is gaining* Correspondence: hansh@gachon.ac.kr
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stated.importance along with continuous efforts of many busi-
nesses and health institutions to develop practical prevent-
ive measures through the management of metabolic
syndromes that involve various cerebrovascular and
cardiovascular risk factors.
Various studies have identified metabolic syndromes as
a major predictor of cerebrovascular and cardiovascular
diseases [3], and study results indicated that the occur-
rence and progression of cerebrovascular and cardiovascu-
lar diseases can be prevented through strict management
of metabolic syndrome [4].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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sociation between metabolic syndrome, cerebrovascular
and cardiovascular diseases, and serum uric acid level,
which is well known to be a causal factor for gout. Grad-
ually accumulated evidence support that serum uric acid
level has a significant correlation with each component of
a metabolic syndrome, as it causes hypertension and insu-
lin resistance and is involved in changes in blood triglycer-
ides and cholesterol levels while being associated with
obesity and complications of metabolic syndromes [5,6].
Existing studies conducted with the general population
or workers reported their analysis results that hyperuri-
cemia significantly correlated with blood lead concentra-
tions [7]. Meanwhile, the results of other studies verified
relatively high serum uric acid levels and high inci-
dence rates of gout in people with long-term lead ex-
posure [8,9]; as such, an integrated approach for the
management of long-term lead exposure and hyper-
uricemia, as well as metabolic syndrome, is necessary
from the perspective of occupational environment
medicine.
Until the present, only a few domestic studies have ana-
lyzed the relationship between hyperuricemia and meta-
bolic syndrome; in particular, it is difficult to find domestic
and international case studies analyzing the relationship
between occupational lead exposure, hyperuricemia, and
metabolic syndrome. Therefore, this study aimed to exam-
ine the relationship between blood lead level and serum
uric acid concentration, and the association between hy-
peruricemia and the occurrence of metabolic syndrome in
male workers involved in steelmaking [10], which requires




Health screenings were conducted for a domestic steel-
maker between May 15 and June 5, 2012, in which 2,133
of total 2,157 target workers were screened. Among the
target workers, most were male workers, accounting for
2,097 subjects (97.2%), 765 (36.5%) of whom were work-
ing in the steelmaking process. Among them, 759 male
workers participated in the survey. Excluding the 6 male
steelmaking workers who did not participate in the an-
thropometry or blood testing or who provided inad-
equate responses to the survey, a total of 759 workers
were finally selected as research subjects.
Anthropometric measurements and surveys
Height and weight were measured using an automatic
body measurement device, and a tape measure was used
to measure the waist circumference on the midpoint be-
tween the bottom part of the ribs and the upper part of
the pelvic bones horizontal to the ground. Blood pressurewas measured using an automatic blood pressure measur-
ing system after more than 5 minutes of steady state; when
the systolic and diastolic pressures were 140 and 90 mm
Hg or higher, respectively, the lower value was selected
after a repeated measurement taken after more than
10 minutes of rest. Body mass index (BMI) was calculated
by dividing weight (kg) by the square of height (m).
Through a self-reported survey, medical history of
hypertension, diabetes, and dyslipidemia, and the use of
medication therapy, smoking and drinking habits, and
exercise, were examined. Survey data on smoking and
drinking habits (considering the different types of alco-
hol) were presented in pack-years and days/week, respect-
ively. Exercise was defined as a minimum of 20 minutes of
workout per day until feeling out of breath and was
expressed in frequency (days/week).
Blood and urine tests
After at least 8 hours of fasting, venous blood samples
were collected from the subjects and fasting glucose,
total cholesterol, triglyceride, high-density lipoprotein
(HDL) cholesterol, aspartate aminotransferase (AST), ala-
nine aminotransferase (ALT), γ-glutamic transpeptidase
(γ-GTP), creatinine, blood lead, and serum uric acid con-
centrations were measured. The blood lead concentration
analysis was performed using atomic absorption spectro-
photometry (AAnalyst 600, PerkinElmer, Finland), and
serum uric acid concentration was measured using Uri-
case EMST method (Hitachi 747 automatic analyzer, Hita-
chi, Tokyo, Japan). For low-density lipoprotein (LDL)
cholesterol, the value calculated using the Friedewald for-
mula, LDL (mg/dL) = TC (mg/dL) − HDL (mg/dL) − TG
(mg/dL)/5, was used when the triglyceride level was lower
than 400 mg/dL and the direct measurement method
through the homogenous method was used if the trigly-
ceride level exceeded 400 mg/dL.
Definition of metabolic syndrome
By applying the criteria of the American Heart Association/
National Heart Lung and Blood Institute published in 2005
[11], metabolic syndrome was defined when 3 or more of
the following 5 risk factors were applicable: (1) waist cir-
cumference of 90 cm or greater, (2) blood triglyceride
concentrations of 150 mg/dL or higher or being under
medication therapy, (3) blood HDL level lower than
40 mg/dL or being under medication therapy, (4) sys-
tolic pressure of 130 mm Hg or higher or diastolic
pressure of 85 mm Hg or higher or being under medica-
tion therapy, and (5) fasting glucose level of 100 mg/dL or
higher or being under medication therapy.
Statistical analysis
Statistical analysis was performed using SPSS (version
18.0). Hyperuricemia was defined as a serum uric acid







Mean (SD) Mean (SD)
Age (years) 42.3 (10.9) 38.1 (10.3) 0.000*
Waist circumference (cm) 83.5 (7.2) 85.5 (7.5) 0.001*
Body mass index (kg/m2) 24.1 (2.6) 24.9 (2.9) 0.001*
Systolic blood
pressure (mmHg)
118.3 (12.1) 119.8 (11.5) 0.135
Diastolic blood
pressure (mmHg)
76.2 (9.7) 77.4 (9.8) 0.142
Fasting blood
glucose (mg/dL)
98.5 (21.4) 94.0 (11.5) 0.000*
Total cholesterol (mg/dL) 194.0 (34.6) 199.7 (34.9) 0.054
LDL-cholesterol (mg/dL) 110.0 (30.7) 110.6 (34.8) 0.829
HDL-cholesterol (mg/dL) 54.0 (11.9) 51.1 (10.9) 0.004*
Triglyceride (mg/dL) 157.0 (116.0) 209.0 (161.4) 0.000*
AST (IU/L) 24.5 (13.3) 28.7 (14.7) 0.001*
ALT (IU/L) 27.4 (25.8) 35.2 (27.3) 0.001*
γ-GTP (IU/L) 44.0 (46.7) 59.2 (60.8) 0.002*
Serum creatinine (mg/dL) 0.9 (0.1) 1.0 (0.1) 0.000*
Smoking (pack-year) 10.7 (11.9) 11.2 (11.6) 0.622
Drinking (days/week) 1.7 (1.9) 1.9 (1.3) 0.037*
Exercise (days/week) 1.8 (1.7) 1.5 (1.7) 0.029*
Blood lead (μg/dL)‡ 3.3 (1.8) 3.8 (1.8) 0.003*
*: p < 0.05 by t-test.
†: Serum uric acid level ≥7 mg/dL.
‡: Geometric mean (Geometric standard deviation).
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was performed to determine whether a hyperuricemia-
dependent difference existed in the anthropometric mea-
surements, blood test results, and living habits. As blood
lead concentration showed a distribution skewed to the
left, geometric means and standard deviations were cal-
culated after performing natural log transformation. To
analyze the relationship between hyperuricemia and
metabolic syndrome, we performed a logistic regres-
sion analysis. For variables other than hyperuricemia, a
multivariate logistic regression analysis was performed
by including them in the model as confounding vari-
ables after confirming multicollinearity. In addition,
the relationship between blood lead concentration and
hyperuricemia was analyzed. Blood lead concentration
was set as an explanatory variable by classifying it in
tertiles, and a multivariate logistic regression analysis
was performed by including them in the model as con-
founding variables after confirming multicollinearity
among other variables, excluding the components of
metabolic syndrome.
Results
Hyperuricemia-dependent clinical characteristics of the
subjects
The healthy (without hyperuricemia) group had 577 sub-
jects, and the hyperuricemia group had 182 subjects.
The mean (standard deviation) for serum uric acid con-
centration was 5.5 (0.9) mg/dL in the healthy group and
7.8 (0.7) mg/dL in the hyperuricemia group (Table 1).
Compared with the healthy group, the mean age was sig-
nificantly lower and the mean waist circumference and
BMI were significantly higher in the hyperuricemia
group. In the hyperuricemia group, fasting glucose and
HDL-cholesterol levels were significantly lower, whereas
triglycerides, AST, ALT, γ-GTP, and serum creatinine
levels were significantly higher compared to those in the
healthy group. Weekly drinking frequency was signifi-
cantly higher but weekly exercise frequency was signifi-
cantly lower in the hyperuricemia group than in the
healthy group. The geometric mean (standard deviation)
of the blood lead concentrations was significantly higher
in the hyperuricemia group, at 3.8 (1.8) μg/dL, than in
the healthy group, at 3.3(1.8) μg/dL.
Relationship between hyperuricemia and the occurrence
of metabolic syndrome
Hyperuricemia was found to be significantly associated
with the occurrence of metabolic syndrome through the
univariate (model 1; Table 2) and multivariate logistic re-
gression analyses, the latter being adjusted for age and
blood lead concentration (model 2); additionally adjusted
for smoking, drinking, and exercise habits (model 3);
and for LDL-cholesterol, γ-GTP, and serum creatininelevels (model 4). In addition, age and γ-GTP level were
found to be significantly associated with metabolic
syndrome.Association between blood lead concentration and the
occurrence of hyperuricemia
In the univariate logistic regression analysis (model 1),
the odds ratio for hyperuricemia increased as the blood
lead concentration increased in relation to 1 quartile
(Table 3). Blood lead concentration was found to have a
significant association with hyperuricemia in the multi-
variate logistic regression analysis models respectively
adjusted for age, BMI, and γ-GTP level (model 2); add-
itionally adjusted for smoking, drinking, and exercise
habits (model 3); and adjusted for serum creatinine
(model 4). In addition, a significant association was ob-
served between hyperuricemia, and BMI, γ-GTP level,
smoking habit, and serum creatinine level, among which
serum creatinine level particularly showed a high odds
ratio of 16.877, indicating a very high degree of associ-
ation with hyperuricemia.
Table 2 Multiple logistic regression analysis demonstrating relationship between hyperuricemia and metabolic
syndrome* in four models
Variables Odds ratio (95% confidence interval)
Model 1 Model 2 Model 3 Model 4
Hyperuricemia (≥7 mg/dL)
No 1.000 1.000 1.000 1.000
Yes 1.533 (1.014 ~ 2.317) 2.016 (1.296 ~ 3.135) 1.939 (1.242 ~ 3.026) 1.787 (1.125 ~ 2.839)
Age (years) 1.057 (1.037 ~ 1.077) 1.055 (1.032 ~ 1.077) 1.049 (1.026 ~ 1.073)
log transformed blood lead (μg/dL) 0.855 (0.414 ~ 1.768) 0.822 (0.394 ~ 1.715) 0.789 (0.370 ~ 1.681)
Smoking (pack-year) 1.007 (0.991 ~ 1.024) 1.005 (0.988 ~ 1.022)
Drinking (days/week) 1.035 (0.906 ~ 1.183) 0.948 (0.820 ~ 1.097)
Exercise (days/week) 0.941 (0.837 ~ 1.057) 0.969 (0.861 ~ 1.091)
LDL-cholesterol (mg/dL) 1.002 (0.996 ~ 1.008)
γ-GTP (IU/L) 1.008 (1.005 ~ 1.012)
Serum creatinine (mg/dL) 0.433 (0.077 ~ 2.442)
*: Defined as the presence of at least three of the following components : waist circumference ≥90 cm, triglycerides ≥150 mg/dL or on drug treatment, HDL-
cholesterol < 40 mg/dL or on drug treatment, SBP ≥130 or DBP ≥85 mmHg or on drug treatment, and fasting glucose ≥100 mg/dL or on drug treatment.
Model 1: not adjusted.
Model 2: adjusted by age, log transformed blood lead.
Model 3: adjusted for model 2 plus smoking, drinking, exercise.
Model 4: adjusted for model 3 plus LDL-cholesterol, γ-GTP, serum creatinine.
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This study examined the association between hyperurice-
mia and metabolic syndrome, and the association between
blood lead and serum uric acid concentrations. Hyperuri-
cemia showed a significant association with metabolic
syndrome even in the results adjusted for confounding
variables, whereas lead was shown to be associated with




Tertile group (blood lead, μg/dL)
I (< 2.61) 1.000
II (2.61 ~ 4.50) 1.676 (1.091 ~ 2.576) 1.971 (
III (>4.50) 1.890 (1.236 ~ 2.889) 2.286 (
Age (years) 0.951 (
Body mass index (kg/m2) 1.098 (





*: Serum uric acid level ≥7 mg/dL.
Model 1: not adjusted.
Model 2: adjusted by age, body mass index, γ-GTP.
Model 3: adjusted for model 2 plus smoking, drinking, exercise.
Model 4: adjusted for model 3 plus serum creatinine.According to existing studies [13,14], an increase in
serum uric acid concentration is thought to partially con-
tribute to an increase in blood pressure via the activation
of the renin-angiotensin-aldosterone system by inducing
renal vascular inflammation, preglomerular arteriolopathy,
tubulointerstitial inflammation and fibrosis. Serum uric
acid concentration also seems to interfere with blood ves-
sel expansion by decreasing the response of blood vesselsssociation between blood lead level and hyperuricemia*
dds ratio (95% confidence interval)
odel 2 Model 3 Model 4
1.000 1.000 1.000
1.258 ~ 3.087) 1.902 (1.211 ~ 2.989) 1.763 (1.116 ~ 2.784)
1.460 ~ 3.579) 2.182 (1.389 ~ 3.430) 1.982 (1.254 ~ 3.132)
0.934 ~ 0.967) 0.943 (0.924 ~ 0.962) 0.945 (0.925 ~ 0.965)
1.031 ~ 1.168) 1.099 (1.033 ~ 1.170) 1.096 (1.030 ~ 1.168)
1.003 ~ 1.010) 1.005 (1.002 ~ 1.009) 1.005 (1.002 ~ 1.009)
1.017 (0.999 ~ 1.035) 1.020 (1.002 ~ 1.039)
1.076 (0.944 ~ 1.226) 1.085 (0.951 ~ 1.238)
0.950 (0.853 ~ 1.058) 0.938 (0.841 ~ 1.046)
16.877 (3.388 ~ 84.073)
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endothelial dysfunction through interference in the excre-
tion process of nitric oxide (NO) from vascular endothelial
cells by expressing toxicity directly on the blood vessels
[15,16]. In this regard, a study reported that when the ac-
tivity of xanthine oxidase, which is involved in the uric
acid generation process, was inhibited by administering
allopurinol to patients, blood flow was improved along
with vasodilation [17].
Whether serum uric acid level independently influ-
ences the increase in blood glucose level is controversial.
While there are reports on increased insulin resistance
due to certain serum uric acid levels increasing blood
flow and causing vasodilation to interfere with the action
of nitric oxide, which facilitates glucose absorption [18],
other results suggest that hyperuricemia is caused by
hyperinsulinemia due to insulin resistance acting on the
renal tubules to facilitate the reabsorption of uric acid
[19,20]. These results suggest an interaction between
uric acid and insulin levels. However, the mean fasting
glucose level in the hyperuricemia group was signifi-
cantly lower than that in the healthy group in this study,
contradicting the results of existing studies. Upon con-
sidering the results of recent related studies, a decreased
fasting glucose level in patients with hyperuricemia is
possibly due to the increase in uric acid excretion caused
by the glomerular hyperfiltration when hyperglycemia is
maintained [21,22]. However, additional research is ne-
cessary in the future to validate this hypothesis.
The effects of serum uric acid level on dyslipidemia
have not yet been clearly identified; however, according
to recent studies, the increase in uric acid concentration
seems to reduce the function of lipid peroxidase and
lipoprotein lipase, which are involved in lipolysis, while
the process of decreased nitric oxide excretion from
blood vessels is believed to affect the progression of dys-
lipidemia [23,24]. In this study, the total cholesterol and
LDL-cholesterol levels in the hyperuricemia group were
not statistically significant, but the mean levels were still
higher compared to those in the healthy group. Mean-
while, triglyceride levels were significantly higher in the
hyperuricemia group, with significantly lower HDL-
cholesterol levels, than in the healthy group. In particu-
lar, the levels of the triglycerides related to metabolic
syndrome showed the greatest difference in mean values
when compared with the other parameters, which seems
to be due to the decreased function of the tricarboxylic
acid cycle with the increased oxidative stress in the mito-
chondria of liver cells as the uric acid synthesis increased
due to purine metabolism, resulting in slower triglyceride
metabolism and an increase in lipogenesis [25].
Regarding the association between obesity and serum
uric acid concentration, it is known that obese individ-
uals mostly consume meat, with high intake of purine,which results in an increase in uric acid concentration
[26], and hyperuricemia is caused by the facilitation of
uric acid reabsorption in the renal tubules due to high
insulin resistance. These results point to obesity as the
cause of hyperuricemia [27,28]. However, based on the
various correlations identified so far, such as the close
association between insulin resistance and nitric oxide
synthesis dysfunction in vascular endothelial cells and
the claim that uric acid interferes with the nitric oxide
excretion process [18], the increase in the risk for fatty
liver in proportion to the purine metabolism-induced
uric acid synthesis triggered by the deterioration in
mitochondria function in liver cells [25], and the contri-
bution of the reduced mitochondria functioning to the
fat accumulation in muscles and liver in a study with a
non-obese elderly population [29], hyperuricemia itself
seems to partially contribute to obesity. This finding
warrants additional research in the future.
In this study, the hyperuricemia group showed a sig-
nificantly higher mean blood lead concentration than
that in the healthy group. The subjects’ geometric mean
(standard deviation) blood lead concentration was ap-
proximately 3.4 (1.8) μg/dL, which was significantly
lower than 25.0 μg/dL [30], the blood lead concentration
designated by the Centers for Disease Control and Pre-
vention (CDC) as affecting the physiological health of
adults, and even below the recommended upper limit
level of 5.0 μg/dL for children in 2012 [31]. However, in
our univariate and multivariate regression analyses, the
risk of hyperuricemia was shown to increase even at low
blood lead concentrations between 2.61 and 4.50 μg/dL.
Uric acid is synthesized through the metabolism of
purine, and humans are known to have a relatively high
level of serum uric acid concentration compared with
other mammals, as humans do not possess the enzyme
for metabolizing uric acid [32]. Therefore, to maintain
an appropriate level of serum uric acid, males need to
excrete a daily volume of 600–700 mg of uric acid
through the glomeruli, and proximal and distal tubules
of the kidney; ascending loop; and collecting duct. If kid-
ney functioning is reduced, the probability of hyperuri-
cemia becomes relatively high [33]. Furthermore, in this
study, serum creatinine level and hyperuricemia showed
a positive association, which is consistent with the exist-
ing study results that renal functioning affects serum
uric acid levels.
In fact, according to recent studies, an increase in
blood lead concentration caused a reduction in esti-
mated glomerular filtration rate (eGFR) even at a blood
lead concentration lower than 10.0 μg/dL [34]. In addition
to the glomeruli, blood lead causes the atrophy and hyper-
plasia of the tubular epithelial cells and increases the risk
for hyperuricemia by reducing secretory functions to
cause interstitial fibrosis and inflammation [7,35,36]. In
Lee et al. Annals of Occupational and Environmental Medicine 2013, 25:27 Page 6 of 7
http://www.aoemj.com/content/25/1/27addition, when blood lead concentration is higher than
1.2 μg/dL, the risk for gout reportedly increases with the
reduction in uric acid excretion ability of the kidney [37].
An independent association with hyperuricemia was ob-
served for smoking and γ-GTP level; however, it is too early
to assume that both are direct risk factors for hyperurice-
mia, as existing studies report inconsistent results, suggest-
ing the need to conduct a prospective study [38-40].
The steelmaking company investigated in this study
was an independent steelmaker largely divided into
steelmaking and rolling processes. The steelmaking
process exposes workers to lead fumes during the dis-
solving process, during which metal containing impur-
ities is melted [41]. In fact, according to a study that
measured ambient lead concentration using individual
samples during the steelmaking process, most of the
samples showed lead concentrations exceeding 50% of
the domestic threshold (0.05 mg/m3), indicating that
the steelmaking process require attention regarding
occupational lead exposure, along with the iron mak-
ing process, in which metal is extracted by dissolving
ore [41-43]. In addition, the workers involved in iron-
making processes were exposed to mineral dust, noise,
hyperthermia, sulfur dioxide (SO2), carbon monoxide
(CO), and hydrogen sulfide (H2S), but none of the
causative factors of hyperuricemia identified by previ-
ous studies was found.
This study has its significance in providing results that
controlled task properties and sex by limiting the sub-
jects to male workers from a steelmaking company
known to have the most number of lead handling pro-
cesses among other metal industries, in comparison with
existing studies that did not match task properties while
targeting the general public or workers as subjects. It is
also significant in that its simultaneous analyses revealed
that hyperuricemia is significantly associated with meta-
bolic syndrome and that low levels of blood lead can
affect hyperuricemia.
This study has the following limitations: First, it is a
cross-sectional study, and a causal relationship between
blood lead level, serum uric acid level, and metabolic
syndrome could not be established while attempting to
explain the intervariable relationships using various
studies in the existing literature. Second, recall bias might
have existed, as the smoking, drinking, and exercise
habits, and drug therapy were examined through sur-
veys; this bias was minimized through the comparison
between existing survey data for identical subjects.
Third, no survey was conducted on diet related to
serum uric acid concentration; it was partially con-
trolled as the workers took the same meal twice a day
at the company canteen while working 3 shifts, but a
more accurate investigation needs to be conducted.
Lastly, as it is an analysis for a particular group, ourstudy was limited in generalizing the results to all
population groups. In a group without occupational ex-
posure, identical physiological mechanisms due to blood
lead levels were reported [44]. However, a study with a
general population group is needed in the future.
At present, with the prevention and management of
workplace workers’ cerebrovascular and cardiovascular dis-
eases becoming increasingly important, attention should
be given to serum uric acid concentration, which has been
regarded as a causal factor only for gout. In particular, from
the perspective of occupational environment medicine, hy-
peruricemia should be managed in individuals who are
likely to be exposed to lead over a longer period of time for
occupational and environmental reasons. The results of
this study suggest that a risk for hyperuricemia exists even
at low blood lead concentrations. Thus, it is necessary to
conduct a large-scale prospective study to identify any
causal relationship.
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